BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

446 related articles for article (PubMed ID: 21037487)

  • 1. Taxane-based regimens as a risk factor for chemotherapy-induced amenorrhea.
    Najafi S; Djavid GE; Mehrdad N; Rajaii E; Alavi N; Olfatbakhsh A; Najafi M; Bahrami A; Heidari K
    Menopause; 2011 Feb; 18(2):208-12. PubMed ID: 21037487
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Incidence of chemotherapy-induced amenorrhea in hormone-sensitive breast cancer patients: the impact of addition of taxanes to anthracycline-based regimens.
    Pérez-Fidalgo JA; Roselló S; García-Garré E; Jordá E; Martín-Martorell P; Bermejo B; Chirivella I; Guzman C; Lluch A
    Breast Cancer Res Treat; 2010 Feb; 120(1):245-51. PubMed ID: 19575291
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incidence of chemotherapy-induced amenorrhea in premenopausal patients with breast cancer following adjuvant anthracycline and taxane.
    Okanami Y; Ito Y; Watanabe C; Iijima K; Iwase T; Tokudome N; Takahashi S; Hatake K
    Breast Cancer; 2011 Jul; 18(3):182-8. PubMed ID: 21394515
    [TBL] [Abstract][Full Text] [Related]  

  • 4. NSAS-BC02 substudy of chemotherapy-induced amenorrhea (CIA) in premenopausal patients who received either taxane alone or doxorubicin(A) cyclophosphamide(C) followed by taxane as postoperative chemotherapy.
    Iwamoto T; Hara F; Uemura Y; Mukai H; Watanabe T; Ohashi Y
    Breast Cancer Res Treat; 2020 Jul; 182(2):325-332. PubMed ID: 32462261
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Incidence of chemotherapy-induced, long-term amenorrhea in patients with breast carcinoma age 40 years and younger after adjuvant anthracycline and taxane.
    Fornier MN; Modi S; Panageas KS; Norton L; Hudis C
    Cancer; 2005 Oct; 104(8):1575-9. PubMed ID: 16134178
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Determinants of recovery from amenorrhea in premenopausal breast cancer patients receiving adjuvant chemotherapy in the taxane era.
    Minisini AM; Menis J; Valent F; Andreetta C; Alessi B; Pascoletti G; Piga A; Fasola G; Puglisi F
    Anticancer Drugs; 2009 Jul; 20(6):503-7. PubMed ID: 19339872
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chemotherapy-induced amenorrhea, menopause-specific quality of life, and endocrine profiles in premenopausal women with breast cancer who received adjuvant anthracycline-based chemotherapy: a prospective cohort study.
    Yoo C; Yun MR; Ahn JH; Jung KH; Kim HJ; Kim JE; Park JY; Park KO; Yoon DH; Kim SB
    Cancer Chemother Pharmacol; 2013 Sep; 72(3):565-75. PubMed ID: 23842722
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Classical CMF regimen as adjuvant chemotherapy for triple-negative breast cancer may be more effective compared with anthracycline or taxane-based regimens.
    Wang S; Shi Y; Yuan Z; Wang X; Liu D; Peng R; Teng X; Qin T; Peng J; Lin G; Jiang X
    Med Oncol; 2012 Jun; 29(2):547-53. PubMed ID: 21528408
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis of chemotherapy-induced amenorrhea rates by three different anthracycline and taxane containing regimens for early breast cancer.
    Han HS; Ro J; Lee KS; Nam BH; Seo JA; Lee DH; Lee H; Lee ES; Kang HS; Kim SW
    Breast Cancer Res Treat; 2009 May; 115(2):335-42. PubMed ID: 18506620
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of three adjuvant chemotherapy regimes using an extended log-logistic model in women with operable breast cancer.
    Faradmal J; Kazemnejad A; Khodabakhshi R; Gohari MR; Hajizadeh E
    Asian Pac J Cancer Prev; 2010; 11(2):353-8. PubMed ID: 20843115
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The rates of chemotherapy-induced amenorrhea in patients treated with adjuvant doxorubicin and cyclophosphamide followed by a taxane.
    Tham YL; Sexton K; Weiss H; Elledge R; Friedman LC; Kramer R
    Am J Clin Oncol; 2007 Apr; 30(2):126-32. PubMed ID: 17414460
    [TBL] [Abstract][Full Text] [Related]  

  • 12. What lies behind chemotherapy-induced amenorrhea for breast cancer patients: a meta-analysis.
    Zhao J; Liu J; Chen K; Li S; Wang Y; Yang Y; Deng H; Jia W; Rao N; Liu Q; Su F
    Breast Cancer Res Treat; 2014 May; 145(1):113-28. PubMed ID: 24671358
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prospective observational study of chemotherapy-induced alopecia after sequential FEC + taxane and the effects of age in breast cancer patients.
    Fujii T; Ichiba K; Honda C; Tokuda S; Nakazawa Y; Ogino M; Kurozumi S; Obayashi S; Yajima R; Shirabe K
    Breast Cancer; 2021 Mar; 28(2):329-334. PubMed ID: 32944881
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Impact of Age on Quality of Life in Breast Cancer Patients Receiving Adjuvant Chemotherapy: A Comparative Analysis From the Prospective Multicenter Randomized ADEBAR trial.
    Leinert E; Singer S; Janni W; Harbeck N; Weissenbacher T; Rack B; Augustin D; Wischnik A; Kiechle M; Ettl J; Fink V; Schwentner L; Eichler M
    Clin Breast Cancer; 2017 Apr; 17(2):100-106. PubMed ID: 27884722
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The risk of amenorrhea is related to chemotherapy-induced leucopenia in breast cancer patients receiving epirubicin and taxane based chemotherapy.
    Zhou W; Ding Q; Liang X; He Z; Zha X; Liu X; Wang S
    PLoS One; 2012; 7(5):e37249. PubMed ID: 22615953
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selection of adjuvant chemotherapy for treatment of node-positive breast cancer.
    Trudeau M; Charbonneau F; Gelmon K; Laing K; Latreille J; Mackey J; McLeod D; Pritchard K; Provencher L; Verma S
    Lancet Oncol; 2005 Nov; 6(11):886-98. PubMed ID: 16257797
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness of an Adjuvant Chemotherapy Regimen for Early-Stage Breast Cancer: A Systematic Review and Network Meta-analysis.
    Fujii T; Le Du F; Xiao L; Kogawa T; Barcenas CH; Alvarez RH; Valero V; Shen Y; Ueno NT
    JAMA Oncol; 2015 Dec; 1(9):1311-8. PubMed ID: 26402167
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum epidermal growth factor is associated with prognosis and hormone receptor status in patients with HER2-positive metastatic breast cancer treated with first-line trastuzumab plus taxane chemotherapy.
    Kim JW; Kim JH; Im SA; Lee KH; Kim JS; Kim TY; Han SW; Jeon YK; Oh DY; Kim TY; Park IA
    Cancer Chemother Pharmacol; 2013 Nov; 72(5):1023-9. PubMed ID: 24036907
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Goserelin versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy in premenopausal patients with node-positive breast cancer: The Zoladex Early Breast Cancer Research Association Study.
    Jonat W; Kaufmann M; Sauerbrei W; Blamey R; Cuzick J; Namer M; Fogelman I; de Haes JC; de Matteis A; Stewart A; Eiermann W; Szakolczai I; Palmer M; Schumacher M; Geberth M; Lisboa B;
    J Clin Oncol; 2002 Dec; 20(24):4628-35. PubMed ID: 12488406
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Medical treatment of early breast cancer: chemotherapy].
    Ejlertsen B; Kamby C
    Ugeskr Laeger; 2007 Sep; 169(37):3070-2. PubMed ID: 17877950
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.